(Q39228634)

10 September 2017

title

Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy (English)

1 reference

10 September 2017

1 reference

Barth RH

1

1 reference

10 September 2017

DeVincenzo N

series ordinal

2

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 September 1996

1 reference

10 September 2017

1 reference

10 September 2017

volume

50

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

929-936

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.1996.393

10 September 2017

exact match

0 references

cites work

Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Pharmacokinetics of vancomycin in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Vancomycin redistribution: dosing recommendations following high-flux hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Disposition of vancomycin during hemofiltration

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Removal of vancomycin by high-flux hemodialysis membranes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Comparison of the effects of three haemodialysis membranes on vancomycin disposition

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Vancomycin dosing in haemodialysis patients and Bayesian estimate of individual pharmacokinetic parameters.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Monitoring serum vancomycin levels: climbing the mountain because it is there?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Comparison of fluorescence polarization immunoassay and bioassay of vancomycin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Vancomycin therapeutic drug monitoring: is it necessary?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Pharmacokinetic optimisation of vancomycin therapy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Why monitor peak vancomycin concentrations?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

https://api.crossref.org/works/10.1038%2FKI.1996.393

1 reference

7 January 2021

Time-kill studies with oxacillin, vancomycin, and teicoplanin versus Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Why monitor peak vancomycin concentrations?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Necessity of a loading dose when using vancomycin in critically ill patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Mode of action and in-vitro activity of vancomycin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Emergence of vancomycin resistance in coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Influence of bacterial adherence to intravascular catheters on in-vitro antibiotic susceptibility

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Penetration into tissues of various drugs active against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

The in-vitro degradation at 37 degrees C of vancomycin in serum, CAPD fluid and phosphate-buffered saline

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Pharmacokinetics of vancomycin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.393

7 January 2021

Identifiers

DOI

10.1038/KI.1996.393

1 reference

Dimensions Publication ID

10 September 2017

1025728216

0 references

Fatcat ID

release_hgmz6z6os5hpjcckrbc4c6cr7u

0 references

1 reference